Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to explore safety, tolerability, including the maximum tolerated dose and the recommended Phase II dose (RP2D), and antitumor activity of NMS-03592088 in adult patients with relapsed or refractory Acute Myeloid Leukemia (AML) or Chronic Myelomonocytic Leukemia (CMML).
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
US only:
Other protocol specific inclusion/exclusion criteria may apply
Primary purpose
Allocation
Interventional model
Masking
200 participants in 1 patient group
Loading...
Central trial contact
Anders Elm Pedersen
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal